4-year arthritis drug study shows promise for kids
NCT ID NCT03769168
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study looked at the long-term safety and effectiveness of the drug secukinumab in children with two types of juvenile idiopathic arthritis: juvenile psoriatic arthritis and enthesitis related arthritis. 55 children who had already completed a previous study continued taking secukinumab for up to 4 years. The goal was to see if the drug kept working and remained safe over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Childrens Hospital
Cincinnati, Ohio, 45229, United States
-
Legacy Emanuel Research Hospital Portland
Portland, Oregon, 97232, United States
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Hamburg, 22081, Germany
-
Novartis Investigative Site
Saint Augustin, 53757, Germany
-
Novartis Investigative Site
Genova, GE, 16147, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Krakow, 31503, Poland
-
Novartis Investigative Site
Moscow, 119991, Russia
-
Novartis Investigative Site
Saint Petersburg, 194100, Russia
-
Novartis Investigative Site
Voronezh, 394036, Russia
-
Novartis Investigative Site
Yekaterinburg, 620149, Russia
-
Novartis Investigative Site
Panorama, Western Cape, 7500, South Africa
-
Novartis Investigative Site
Cape Town, 7925, South Africa
-
Novartis Investigative Site
Santiago de Compostela, Galicia, 15706, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Istanbul, Halkali, 34303, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, TUR, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, 06230, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, 34093, Turkey (Türkiye)
-
St Lukes Intermountain Research Center
Boise, Idaho, 83702, United States
Conditions
Explore the condition pages connected to this study.